Open-Source Tools for Value Assessment

While many advancements have been made thus far in the progression toward value-based health care, there are persistent challenges in the measurement of value. In order to deliver value-based care, health care decision makers, eg, insurers and health system administrators, need value data at their fingertips—data that are relevant to their own context and reflect…

At ISPOR: The effect of RA medication choice on costs

For those who are attending the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) conference this next week in Baltimore, please check out my poster titled: THE EFFECT OF MEDICATION CHOICE AFTER TUMOR NECROSIS FACTOR INHIBITOR (TNFI) USE ON THE HEALTHCARE COSTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: AN INSTRUMENTAL VARIABLES APPROACH My co-authors are Ahva…

Modelling medication adherence patterns for patients with serious mental and physical illnesses

Please check out my recent paper titled “Medication Adherence Patterns Among Patients with Multiple Serious Mental and Physical Illnesses” with co-authors Joanna P. MacEwan, Alison R. Silverstein, Darius N. Lakdawalla, Ainslie Hatch and Felicia M. Forma in Advances in Health.   This study is unique because it looks at medication adherence patterns among patients with…

Estimated prevalence of undiagnosed atrial fibrillation in the United States

This paper–written with co-authors Mintu P. Turakhia, Katalin Bognar, Jeffrey Trocio, Younos Abdulsattar, Daniel Wiederkehr, and Dana P. Goldman–is now up at PLOS One.  The study abstract is pasted below. Introduction As atrial fibrillation (AF) is often asymptomatic, it may remain undiagnosed until or even after development of complications, such as stroke. Consequently the observed…

Patient-Centered Formularies: Steps In The Right Direction, But Challenges Remain

That is the title of my latest blog post in Health Affairs with co-author Mark Linthicum.  The premise is as follows: CVS recently announced its new Transform Rheumatoid Arthritis Care initiative, which aims to reshape coverage of rheumatoid arthritis care through “value-based management strategies including outcomes based contracts and a new indication-based formulary for autoimmune…

The gold standard of scientific evidence

That is the title of my latest article in Pharmaceutical Market Europe. An excerpt is below. Randomised controlled trials (RCTs) are regarded as the gold standard of scientific evidence, and for good reason. By randomizsing a treatment across study arms, RCTs eliminate patient-treamtent selection bias, resulting in reliable causal inference. In contrast, in the real…